MedTrace Logo

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

NCT06285318 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 900

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.

Conditions

  • Relapsed/Refractory Multiple Myeloma (RRMM)

Interventions

OTHER

Teclistamab

No Intervention will be administered during the study. Retrospective data analysis using participants medical records collected within this study will be entered into CRF.

OTHER

Talquetamab

No Intervention will be administered during the study. Retrospective data analysis using participants medical records collected within this study will be entered into CRF.

Sponsors & Collaborators

  • Janssen-Cilag Ltd.

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag Limited Clinical Trial · Janssen-Cilag Limited

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-18
Primary Completion
2026-06-30
Completion
2026-09-24

Countries

  • Denmark
  • France
  • Germany
  • Greece
  • Ireland
  • Israel
  • Italy
  • Norway
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06285318 on ClinicalTrials.gov